Index > Vol. 89/2009 > Iss. 3/May > pp. 295-298 > Abstract
Clinical Report | Drug development and adverse reactions, Mucous membranes and granulomatous diseases

Treatment of Disseminated Granuloma Annulare with Low-dose Fumaric Acid

doi: 10.2340/00015555-0647

Abstract:

While localized variants of granuloma annulare are typically self-limited, disseminated granuloma annulare tends to be chronic and often therapy-resistant. Treatment with fumaric acid esters is effective for severe forms of psoriasis. Disseminated granuloma annulare has also been reported to respond to fumaric acid esters. We treated 8 patients (mean age 64.2 years; 4 men, 4 women) with low-dose fumaric acid esters for 1–18 months. One patient showed complete clearance, 4 marked improvement, one slight to moderate improvement and one no response. One patient discontinued treatment due to nausea after one month and another stopped it after 18 months. Five out of 8 patients tolerated the treatment well. Six patients developed transient, mild leucopaenia and one eosinophilia. None of these blood abnormalities necessitated discontinuation of therapy. Low-dose fumaric acid esters significantly improve disseminated granuloma annulare in approximately 63% of patients. Larger, controlled, prospective studies are needed to evaluate its efficacy and safety in this setting.

Authors:

H. Oliver Weber, Claudia Borelli, Martin Röcken and Martin Schaller

Key words:

granuloma annulare; fumaric acid esters; low dose.

References

  1. Smith MD, Downie JB, DiCostanzo D. Granuloma annulare. Int J Dermatol 1997; 36: 326–333.
  2. Dahl MV. Granuloma annulare: long-term follow-up. Arch Dermatol 2007; 143: 946–947. Link to article
  3. Nebesio CL, Lewis C, Chuang TY. Lack of an association between granuloma annulare and type 2 diabetes mellitus. Br J Dermatol 2002; 146: 122–124. Link to article
  4. Fayyazi A, Schweyer S, Eichmeyer B, Herms J, Hemmerlein B, Radzun HJ, et al. Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch Dermatol Res 2000; 292: 384–390. Link to article
  5. Salomon N, Walchner M, Messer G, Plewig G, Rˆcken M. [Bath-PUVA therapy of granuloma annulare. Hautarzt 1999; 50: 275–279. Link to article
  6. Cyr PR. Diagnosis and management of granuloma annulare. Am Fam Physician 2006; 74: 1729–1734.
  7. Breuer K, Gutzmer R, Volker B, Kapp A, Werfel T. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 2005; 152: 1290–1295. Link to article
  8. Eberlein-Konig B, Mempel M, Stahlecker J, Forer I, Ring J, Abeck D. Disseminated granuloma annulare-treatment with fumaric acid esters. Dermatology 2005; 210: 223–226. Link to article
  9. Kreuter A, Gambichler T, Altmeyer P, Brockmeyer NH. Treatment of disseminated granuloma annulare with fumaric acid esters. BMC Dermatol 2002; 2: 5. Link to article
  10. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363–369. Link to article
  11. Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, von Bonin A, Hennekes HH, et al. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 2007; 127: 835–845. Link to article
  12. Litjens NH, Rademaker M, Ravensbergen B, Rea D, van der Plas MJ, Thio B, et al. Monomethylfumarate affects polarization of monocyte-derived dendritic cells resulting in down-regulated Th1 lymphocyte responses. Eur J Immunol 2004; 34: 565–575. Link to article
  13. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26: 2067–2074. Link to article
  14. Ghoreschi K, Mrowietz U, Rˆcken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003; 81: 471–480. Link to article
  15. Yazdi MR, Mrowietz U. Fumaric acid esters. Clin Dermatol 2008; 26: 522–526. Link to article
  16. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40–46. Link to article
  17. Rubant SA, Ludwig RJ, Diehl S, Hardt K, Kaufmann R, Pfeilschifter JM, et al. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol 2008; 128: 326–331.